NeoChord has raised $20.6 million in a new round of equity financing, according to a recently posted SEC filing. The St. Louis Park, Minn.-based company offered Series D preferred stock in the round, with the first sale noted on October 31, according to the filing. A total of 27 anonymous investors have joined in the […]
NeoChord said yesterday it closed a $25 million Series D equity financing round to help support its mitral valve repair system intended to treat mitral valve regurgitation. The round was led by U.S. Venture Partners, co-led by Deerfield Management and joined by Baird Capital, St. Louis Park, Minn.-based NeoChord said. “NeoChord has established strong, clinical […]
NeoChord said it won an investigational device exemption from the FDA for a clinical trial of its mitral valve repair technology. St. Louis Park, Minn.-based NeoChord said the 20-site study is a prospective, multicenter, randomized clinical trial of its DS1000 artificial chordae delivery system. “IDE approval is a major milestone for NeoChord and its investors,” president & CEO David […]
Wright Medical COO, ex-Tornier CEO Mowry, steps down Wright Medical (NSDQ:WMGI) said yesterday its exec veep and chief operating officer, and former Tornier (NSDQ:TRNX) CEO, David Mowry will be stepping down from the company on May 6 to pursue other opportunities. The company did not indicate who would take Mowry’s position. Read more
1. AngioDynamics CEO DeVivo is out, ex-Covidien exec Clemmer is in AngioDynamics (NSDQ:ANGO) said today that president & CEO Joseph DeVivo stepped down to “pursue other interests” and was replaced by ex-Covidien bigwig James Clemmer, effective today. DeVivo joined Latham, N.Y.-based AngioDynamics in September 2011. “We thank Joe for his contributions and commitment to AngioDynamics over […]
AdvaMed said it named Shaye Mandle, CEO of Minnesota’s LifeScience Alley trade association, as chairman of its State Medical Technology Alliance. “The medical technology industry is a hallmark of U.S. innovation represented by a community of people dedicated to improving and saving lives. Now more than ever, medical technology has the opportunity to help deliver […]
Neochord said it raised $12.6 million in debt of a hoped-for $20 million funding round to support its DS1000 minimally invasive mitral valve repair system. The Neochord device is designed to allow the implantation of artificial chordae tendinae, thread-like connectors that anchor leaflets of the mitral valve to heart muscle, the Minnesota-based medical device company […]
Minnesota device maker NeoChord won CE Mark approval in the European Union for its DS1000 Mitral Valve Repair system, the company announced this week.
The device allows the implantation of artificial chordae tendinae, thread-like tissues that anchor the leaflets of the mitral valve to heart muscle. Surgeons can use the device to repair mitral valve prolapse via a transapical, off-pump procedure, according to the company.
Edwards Lifesciences Corp. (NYSE:EW) landed a new four-year $500 million credit facility after canceling a prior one a couple months early.
The old facility was a five-year deal, also for $500 million, that was scheduled to mature September 29, 2011.
NeoChord Inc., which is developing innovative medical devices for the heart’s mitral valve, raised $1 million to tide it over before a larger fund-raise and European regulatory approval.
The Minnetonka, Minn.-based company is about one-third of the way through clinical trials in Europe testing its first device, which supplies artificial chordae tendineae — the thread-like tissues that anchor the leaflets of the mitral valve to heart muscle. Surgeons using NeoChord’s technology can implant the artificial chords with a probe-like device through a small incision in the chest.